Pfizer Repayments of Short-Term Debt decreased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $2.05B to $0.00. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher repayments reduce short-term leverage and interest burden, signaling improved financial health and liquidity management.
Cash outflows used to settle debt obligations with maturities of one year or less. This reflects the company's ability t...
Standard line item in the financing section of the cash flow statement for most public companies.
other_repayments_of_short_term_debt| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $1.00M | -$1.00M | $971.75M | $971.75M | $971.75M | $971.75M | $0.00 | $0.00 | $0.00 | $3.00M | $328.00M | $4.52B | $2.92B | $3.45B | $2.05B | $151.00M | $0.00 |
| QoQ Change | — | — | -200.0% | >999% | +0.0% | +0.0% | +0.0% | -100.0% | — | — | — | >999% | >999% | -35.4% | +18.1% | -40.7% | -92.6% | -100.0% |
| YoY Change | — | — | — | — | — | >999% | >999% | -100.0% | -100.0% | -100.0% | -99.7% | — | — | — | >999% | +524.4% | -96.7% | -100.0% |